Navigation Links
Uroplasty, Inc. Reports Presentations of Urgent(R) PC Studies at the 2008 Society of Urologic Nurses and Associates Annual Symposium
Date:3/3/2008

MINNEAPOLIS, March 3 /PRNewswire-FirstCall/ -- Uroplasty, Inc. (Amex: UPI) announced today the presentation of the findings of three studies on its Urgent(R) PC Neuromodulation System, a proprietary, minimally invasive nerve stimulation device, designed for office-based treatment of overactive bladder (OAB) symptoms, at the Society of Urologic Nurses and Associates (SUNA) Annual Symposium in Tampa, Florida. These retrospective and observational studies examined the use of the Urgent PC to deliver percutaneous tibial nerve stimulation (PTNS) for the treatment of OAB symptoms of urinary urgency, urinary frequency, and urge incontinence.

"These studies found that the Urgent PC is a viable, well-tolerated, nondrug option for the delivery of PTNS for treatment of OAB symptoms. The studies also reported reductions in the frequency of unwanted voids and incontinence, as well as a high level of self-reported patient satisfaction," said Dave Kaysen, the President and Chief Executive Officer of Uroplasty, Inc. "We believe, from a practice perspective, that Urgent PC is an effective, easy-to-administer treatment easily incorporated into routine patient care in an office setting."

In an oral presentation, "Percutaneous Tibial Nerve Stimulation: Revival of an Old Technology for Treatment of Overactive Bladder," Leslie Wooldridge, MSN, RNCS, GNP.F, BCIA-PMBD, Director of the Bladder Control Clinic from Hackley Health at the Lakes Women's Center in Muskegon, Michigan, presented results of 24 patients, who completed the initial twelve, 30-minute weekly Urgent PC treatments. Of the 24 patients, 19 patients with successful results transitioned to maintenance therapy with longer intervals between treatments. Two did not find the Urgent PC effective enough to continue the treatments and three discontinued the treatment for reasons unrelated to the treatment itself. Patients found a reduction in the daily average number of day voids from 11.16 to 8, night voids from 2.46 to 1.09 and incontinence episodes from 3.78 to 0.75.

In a poster presentation, "Percutaneous Tibial Nerve Stimulation (PTNS) Treatment for Overactive Bladder (OAB) Patients in a Community Based Urology Practice," Lesbia Candelaria, RN from Winter Park Urology Associates, Orlando, Florida, conducted a retrospective evaluation of sixteen patients, who successfully completed twelve, 30-minute weekly Urgent PC treatments. Ms. Candelaria collected data on demographics, night voids and subjective patient satisfaction and improvement at the end of the treatment schedule. Of the 16 patients who completed the treatments, 5 were female and 11 were male. The data showed decreases in the average night voids and a high rate of patient satisfaction with the treatment. The response to the survey questions indicated that after 12 treatments:

-- Greater than 50% of the patients improved night voids from a baseline

average of 3.6 to an average of 1.8.

-- Greater than 80% of patients were totally or highly satisfied with the

Urgent PC treatments.

-- Approximately 72% of patients rated themselves as highly or totally

improved.

-- 100% of the patients who answered this question (n=8) said they would

definitely or likely recommend Urgent PC treatments to a friend with

similar symptoms.

In another poster presentation, "Percutaneous Tibial Nerve Stimulator: A Viable Option for Urgency, Frequency, and Urge Incontinence," Vanessa K. Hardy, WHNP, APN, MSN, a urogynecology nurse practitioner from Vanderbilt University Medical Center in Nashville, Tennessee, conducted a retrospective review of 12 Urgent PC patients. Ms. Hardy collected data on primary diagnosis, duration of treatment, and changes in urinary frequency, urgency, and urge incontinence. Following the twelve, 30-minute weekly Urgent PC treatments, 30% of the patients (or 4 patients) reported at least 50% or more improvement in their symptoms.

About the Urgent PC Neuromodulation System

The Urgent PC neuromodulation system is a proprietary, minimally invasive nerve stimulation device designed for office-based treatment of OAB symptoms of urge incontinence, urinary urgency and urinary frequency. Application of neuromodulation therapy targets specific nerve tissue and disrupts the signals that lead to the symptoms of OAB. Uroplasty sells the Urgent PC system in the United States, Canada and countries recognizing the CE mark. Outside of the United States, the Urgent PC is also indicated for the treatment of fecal incontinence.

About Uroplasty, Inc.

Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our primary focus is the commercialization of our Urgent PC system, which we believe is the only FDA- approved non-surgical neurostimulation therapy for the treatment of overactive bladder (OAB) symptoms. We also offer Macroplastique(R) Implants, a bulking agent for the treatment of urinary incontinence. Please visit Uroplasty, Inc. at http://www.uroplasty.com.

Uroplasty, Inc.

David Kaysen, President and CEO, or

Medi Jiwani, Vice President, CFO, and Treasurer,

952.426.6140

EVC Group

Julie Huang/Matt Selinger (Investors)

646.443.6963

Steve DiMattia/Chris Gale (Media)

646.201.5445


'/>"/>
SOURCE Uroplasty, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Uroplasty, Inc. Announces Filing of Registration Statement for Offering of Common Stock
2. Uroplasty, Inc. Reports Record Sales For Second Fiscal Quarter
3. Uroplasty, Inc. Announces Pricing of a Public Offering of Its Common Stock
4. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
5. Haemacure Reports Third Quarter 2007 Results
6. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
7. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
8. MDS Reports Third Quarter 2007 Results
9. Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006
10. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
11. NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... ... , ... Marcy was in a crisis. Her son James, eight, was out of control. Prone ... physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If ... at my other children and say he was going to kill them. If we ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
(Date:6/24/2016)... TX (PRWEB) , ... June 24, 2016 , ... People ... part in Genome magazine’s Code Talker Award, an essay contest in which patients and ... an award to be presented at the 2016 National Society of Genetic Counselors (NSGC) ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & ... (TGIG), has initiated cultivation and processing operations at its production facility, and opened ... , Puradigm is the manufacturer of a complete system of proactive air and ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
(Date:6/24/2016)... 24, 2016  Consumers have taken a more ... placed more emphasis on patient outcomes. ... in the pharmaceutical industry have evolved beyond just ... companies are focusing on becoming more patient-oriented across ... and services that improve health. ...
(Date:6/24/2016)... , June 24, 2016  Global Blood Therapeutics, ... company developing novel therapeutics for the treatment of ... announced the closing of its previously announced underwritten ... at the public offering price of $18.75 per ... were offered by GBT. GBT estimates net proceeds ...
Breaking Medicine Technology: